In­ter­fer­on be­ta-1a can­di­date for COPD ad­vances to PhI­II to test its po­ten­tial against Covid-19

An­oth­er re­pur­posed drug is en­ter­ing Phase III to see if it pass­es the test against Covid-19.

In a small Phase II tri­al, Synair­gen says hos­pi­tal­ized Covid-19 pa­tients who took its in­hal­able in­ter­fer­on be­ta-1a for­mu­la­tion, SNG001, were twice as like­ly to re­cov­er with­in 14 days than pa­tients on a place­bo. CEO Richard Mars­den said the Southamp­ton, UK-based biotech is launch­ing the can­di­date — which was al­ready in de­vel­op­ment for COPD and asth­ma — in­to a 900-per­son Phase III study in the com­ing weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER